JP2010522750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522750A5 JP2010522750A5 JP2010500949A JP2010500949A JP2010522750A5 JP 2010522750 A5 JP2010522750 A5 JP 2010522750A5 JP 2010500949 A JP2010500949 A JP 2010500949A JP 2010500949 A JP2010500949 A JP 2010500949A JP 2010522750 A5 JP2010522750 A5 JP 2010522750A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- independently
- alkyl
- cycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 guanazino Chemical group 0.000 claims description 123
- 150000001875 compounds Chemical class 0.000 claims description 120
- 125000001072 heteroaryl group Chemical group 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 74
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 62
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 60
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 56
- 125000003107 substituted aryl group Chemical group 0.000 claims description 52
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 47
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 44
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 44
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 6
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 6
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 6
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- DTXOCJGLLMAFBX-UHFFFAOYSA-N oxo-[[1-[2-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]ethoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCCOCN1C=CC(=C[NH+]=O)C=C1 DTXOCJGLLMAFBX-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- NCKKMYKNYLIUDP-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1,5-dihydro-1,2,4-triazin-6-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(CC(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O NCKKMYKNYLIUDP-UHFFFAOYSA-N 0.000 claims description 2
- QZHIIMRXMPTCDV-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(4-morpholin-4-ylphenyl)-1,5-dihydro-1,2,4-triazin-6-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(CC(=O)NN=2)C=2C=CC(=CC=2)N2CCOCC2)=C1O QZHIIMRXMPTCDV-UHFFFAOYSA-N 0.000 claims description 2
- NVSARGIJVCFALM-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-(dimethylamino)phenyl]-1,5-dihydro-1,2,4-triazin-6-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(CC(=O)NN=2)C=2C=CC(=CC=2)N(C)C)=C1O NVSARGIJVCFALM-UHFFFAOYSA-N 0.000 claims description 2
- ASXZYSYWBDYVJK-UHFFFAOYSA-N 4-(2,4-dihydroxy-5-propan-2-ylphenyl)-1,3,4,7-tetrahydrofuro[3,4-d]pyrimidine-2,5-dione Chemical compound C1=C(O)C(C(C)C)=CC(C2C3=C(COC3=O)NC(=O)N2)=C1O ASXZYSYWBDYVJK-UHFFFAOYSA-N 0.000 claims description 2
- GKHMRQSMULFODR-UHFFFAOYSA-N 4-(2,4-dihydroxy-5-propan-2-ylphenyl)-6-ethyl-1,3,4,7-tetrahydropyrrolo[3,4-d]pyrimidine-2,5-dione Chemical compound O=C1N(CC)CC(NC(=O)N2)=C1C2C1=CC(C(C)C)=C(O)C=C1O GKHMRQSMULFODR-UHFFFAOYSA-N 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- SWYKTNAHDMJKJU-UHFFFAOYSA-N ethyl 4-(2,4-dihydroxy-5-propan-2-ylphenyl)-6-methyl-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=C(C)NC(=O)NC1C1=CC(C(C)C)=C(O)C=C1O SWYKTNAHDMJKJU-UHFFFAOYSA-N 0.000 claims description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- JZTHQIOOVSRSAV-UHFFFAOYSA-N OC1=C(C=C(C(=C1)O)C(C)C)N1N=CN(CC1=O)CC1=CC=C(C=C1)OC Chemical compound OC1=C(C=C(C(=C1)O)C(C)C)N1N=CN(CC1=O)CC1=CC=C(C=C1)OC JZTHQIOOVSRSAV-UHFFFAOYSA-N 0.000 claims 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical class C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 241000124008 Mammalia Species 0.000 description 17
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 0 ***(*1)C(c2c(*)cc(*)c(*)c2)=**[C@]1O Chemical compound ***(*1)C(c2c(*)cc(*)c(*)c2)=**[C@]1O 0.000 description 1
- NQSKYRRKRPDMFI-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[(4-methoxyphenyl)methyl]-1,5-dihydro-1,2,4-triazin-6-one Chemical compound C1=CC(OC)=CC=C1CN1C(C=2C(=CC(O)=C(C(C)C)C=2)O)=NNC(=O)C1 NQSKYRRKRPDMFI-UHFFFAOYSA-N 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000033014 Plasma cell tumor Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 230000001401 hemangioblastic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92032707P | 2007-03-27 | 2007-03-27 | |
| US60/920,327 | 2007-03-27 | ||
| PCT/US2008/003810 WO2008118391A2 (en) | 2007-03-27 | 2008-03-24 | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522750A JP2010522750A (ja) | 2010-07-08 |
| JP2010522750A5 true JP2010522750A5 (https=) | 2011-05-06 |
| JP5529004B2 JP5529004B2 (ja) | 2014-06-25 |
Family
ID=39739347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500949A Expired - Fee Related JP5529004B2 (ja) | 2007-03-27 | 2008-03-24 | Ｈｓｐ９０阻害剤として有用なトリアジノンおよびジアジノン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8524712B2 (https=) |
| EP (1) | EP2155694B1 (https=) |
| JP (1) | JP5529004B2 (https=) |
| AT (1) | ATE540028T1 (https=) |
| AU (1) | AU2008232354B9 (https=) |
| CA (1) | CA2682665C (https=) |
| ES (1) | ES2395114T3 (https=) |
| TW (1) | TWI427068B (https=) |
| WO (1) | WO2008118391A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006055760A1 (en) | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| CA2653222A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2007267843B2 (en) | 2006-05-25 | 2011-10-13 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| EP2035396B1 (en) | 2006-05-25 | 2014-05-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2007139960A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
| EP2026797A2 (en) | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Method for treating non-hodgkin's lymphoma |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| US8648071B2 (en) | 2008-06-27 | 2014-02-11 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate Hsp90 activity |
| ES2415234T3 (es) * | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| US8106083B2 (en) | 2008-08-08 | 2012-01-31 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| TWI460177B (zh) * | 2009-07-10 | 2014-11-11 | Taiho Pharmaceutical Co Ltd | An azabicyclo compound or a salt thereof |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| WO2011038204A1 (en) | 2009-09-25 | 2011-03-31 | N30 Pharmaceuticals, Llc | Novel dihydropyrimidin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| EP2618666A4 (en) | 2010-09-24 | 2014-04-16 | N30 Pharmaceuticals Inc | NEW DIHYDROPYRIMIDIN-2 (1H) -ON COMPOUNDS AS NEUROKININ-3 RECEPTOR ANTAGONISTS |
| WO2012087943A2 (en) * | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| JP2014520808A (ja) | 2011-07-07 | 2014-08-25 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物を用いた癌の治療 |
| EP2736904B1 (en) * | 2011-07-27 | 2016-03-16 | AB Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| CN116574185A (zh) | 2012-07-25 | 2023-08-11 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| CN113521314A (zh) | 2014-09-17 | 2021-10-22 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| WO2018049092A1 (en) | 2016-09-09 | 2018-03-15 | University Of Cincinnati | Small molecule prolactin receptor inhibitors, pharmaceutical compositions and treatment methods using such inhibitors |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| CN109666024A (zh) * | 2018-03-20 | 2019-04-23 | 兰州大学 | 2-氧嘧啶类化合物及其制备方法和用途 |
| CN110105365B (zh) * | 2019-05-29 | 2021-08-10 | 华中农业大学 | 一种喹啉衍生物VCTb5及其在制备抗癌药物中的应用 |
| CN110105366B (zh) * | 2019-05-29 | 2021-06-01 | 华中农业大学 | 一种喹啉衍生物VCTb9及其在制备抗癌药物中的应用 |
| KR20230035049A (ko) * | 2020-07-02 | 2023-03-10 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| WO2025188973A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4239540A1 (de) * | 1992-11-25 | 1994-05-26 | Asta Medica Ag | Neue heterocyclische Verbindungen mit antiasthmatischer/antiallergischer, entzündungshemmender, positiv inotroper und blutdrucksenkender Wirkung |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| GB0320300D0 (en) * | 2003-08-29 | 2003-10-01 | Cancer Rec Tech Ltd | Pyrimidothiophene compounds |
| EP1675834A4 (en) * | 2003-10-16 | 2008-08-27 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| EP1736472A4 (en) * | 2004-04-15 | 2007-10-31 | Astellas Pharma Inc | 2-aminopyridine derivative |
| CN101189214A (zh) * | 2005-05-03 | 2008-05-28 | 美国陶氏益农公司 | 取代的4，5-二氢-1，2，4-三嗪-6-酮、1，2，4-三嗪-6-酮及其作为杀菌剂的用途 |
| EP2049497A2 (en) * | 2005-05-19 | 2009-04-22 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
| DE102005022977A1 (de) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
-
2008
- 2008-03-24 AU AU2008232354A patent/AU2008232354B9/en not_active Ceased
- 2008-03-24 AT AT08742209T patent/ATE540028T1/de active
- 2008-03-24 US US12/593,147 patent/US8524712B2/en not_active Expired - Fee Related
- 2008-03-24 WO PCT/US2008/003810 patent/WO2008118391A2/en not_active Ceased
- 2008-03-24 ES ES08742209T patent/ES2395114T3/es active Active
- 2008-03-24 EP EP08742209A patent/EP2155694B1/en not_active Not-in-force
- 2008-03-24 JP JP2010500949A patent/JP5529004B2/ja not_active Expired - Fee Related
- 2008-03-24 CA CA2682665A patent/CA2682665C/en not_active Expired - Fee Related
- 2008-03-27 TW TW097110954A patent/TWI427068B/zh not_active IP Right Cessation
-
2013
- 2013-08-28 US US14/012,408 patent/US20130345219A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522750A5 (https=) | ||
| JP2010518085A5 (https=) | ||
| CA2682665A1 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
| JP2010536753A5 (https=) | ||
| CN115605476B (zh) | 取代的三环化合物 | |
| KR102307566B1 (ko) | 신규한 바이사이클릭 브로모도메인 억제제 | |
| CA2683641C (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| JP2009538320A5 (https=) | ||
| JP2009538322A5 (https=) | ||
| JP2009538321A5 (https=) | ||
| RU2018112230A (ru) | Бициклические соединения в качестве ингибиторов atx | |
| JP2013537210A5 (https=) | ||
| KR20190080897A (ko) | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 | |
| JP2016537384A5 (https=) | ||
| JP2022500402A5 (https=) | ||
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| JP2016515098A5 (https=) | ||
| HUP0400718A2 (hu) | PDE7 és PDE4 kettős inhibitorok alkalmazása leukocita aktivitással társult betegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
| JP2014528479A5 (https=) | ||
| JP2012515205A5 (https=) | ||
| JP2018501315A5 (https=) | ||
| CA2684056A1 (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2013505930A5 (https=) | ||
| KR20160104729A (ko) | 암 또는 염증성 질환의 치료를 위한 치환 피롤로피리딘 및 피롤로피라진 | |
| JP2011513475A5 (https=) |